anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 57.66g of plant protein and fibre variety 3 (3.09g leucine), 31.72g butter, 6.62g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
The invention relates to a solvent vehicle for therapeutics comprising a dialkyl ester of adipic acid and, optionally, DMSC, which is particularly useful for therapeutic materials having a low solubility or being insoluble in water. The invention further relates to pharmaceutical compositions which are suitable for parental administration, especially by intramuscular injection, comprising a therapeutically active material dissolved in said solvent vehicle. Solvent vehicles containing di-n-butyl adipate and DMSO, and, if desired, one or more adjuvants, are preferred. Particularly useful are pharmaceutical compositions for the prophylaxis and or treatment of diseases caused by internal parasites, which can be administered by intramuscular injection. A preferred embodiment of the invention is an injectable composition against distomatosis (liver fluke disease) containing proportionally 12.5 g 4,6'-dichloro-4',6-dinitro-2,2'-methylene-diphenol and 30 g of DMSO, completed with di-n-butyl adipate to 100 cm3.[EP0003382A1]
BACKGROUND: Benign tracheal stenosis is relatively rare but remains a significant chronic disease due to its drastic symptoms including dyspnoea and inspiratory stridor, and consequent negative effect on quality of life. Traditionally, the surgical approach by resection of the stenotic tracheal segment has been the therapy of choice. However, endoscopic techniques have arisen and may offer a safe and less invasive alternative.
OBJECTIVES: The aim of the retrospective study was to evaluate procedure-related safety and outcome of endoscopic treatment of benign tracheal stenosis at a single centre.
METHODS: The study included all patients at our institution who between 2013 and 2022 had received endoscopic treatment of benign tracheal stenosis by rigid tracheoscopy, radial incision by electric papillotomy needle and dilation (endoscopic tracheoplasty) followed by triamcinolone acetonide as a local submucosal injection and additionally, from 2020, budesonide inhalation.
RESULTS: A total of 22 patients were treated in a total of 38 interventions, each resulting in immediate improvement of symptoms. There were no peri-interventional complications or mortality. Of the 38 interventions, 11 received no triamcinolone acetonide administration, resulting in a 54.5% recurrence rate after an average of 21.1 (±18.0) months, while 27 had local triamcinolone acetonide, with a 37% recurrence rate. Since 2020, we additionally initiated post-interventional budesonide inhalation as recurrence prophylaxis for newly admitted patients and patients with recurrences(n = 8), of whom only one (12.5%) has to date experienced a recurrence.
CONCLUSION: Our results indicate that endoscopic tracheoplasty offers a safe and successful, minimally invasive alternative to open surgery for patients with benign tracheal stenosis. We recommend local administration of triamcinolone into the mucosa as an additional treatment to decrease the risk of recurrence. However, given the uncontrolled study design and low sample size, safety and effectiveness cannot be conclusively demonstrated. Nonetheless, our findings suggest promising avenues for further investigation. Further studies on the additional benefit of inhaled corticosteroids are warranted.
Only the standard drugs for type 2 diabetes were given. Dapagliflozin was not given in this group.
BACKGROUND: Coronary Heart Disease (CHD) is one of the most common types of cardiovascular disease, and Heart Failure (HF) is an important factor in its progression. We aimed to evaluate the diagnostic value and predictors of multiparametric Cardiac Magnetic Resonance (CMR) in CHD patients with HF.
METHODS: The study retrospectively included 145 CHD patients who were classified into CHD (HF+) (n = 91) and CHD (HF-) (n = 54) groups according to whether HF occurred. CMR assessed LV function, myocardial strain and T1 mapping. Multivariate linear regression analyses were performed to identify predictors of LV dysfunction, myocardial fibrosis, and LV remodeling.
RESULTS: CHD (HF+) group had impaired strain, with increased native T1, ECV, and LVM index. The impaired strain was associated with LVM index (p < 0.05), where native T1 and ECV were affected by log-transformed amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. ROC analysis showed the combination of global circumferential strain (GCS), native T1, and LVM had a higher diagnostic value for the occurrence of HF in CHD patients.<P> Meanwhile, log-transformed NT-proBNP was an independent determinant of impaired strain, increased LVM index, native T1 and ECV.
CONCLUSION: HF has harmful effects on LV systolic function in patients with CHD. In CHD (HF+) group, LV dysfunction is strongly correlated with the degree of LV remodeling and myocardial fibrosis. The combination of the three is more valuable in diagnosing HF than conventional indicators.
Patients receive avelumab IV over 60 minutes on days 1 and 15, and M6620 IV over 60 minutes on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Most of the studies on the cost of intellectual disability are limited to a healthcare perspective or cohorts composed of individuals where the etiology of the condition is a mixture of genetic and non-genetic factors. When used in policy development, these can impact the decisions made on the optimal allocation of resources. In our study, we have developed a static microsimulation model to estimate the healthcare, societal, and lifetime cost of individuals with familial intellectual disability, an inheritable form of the condition, to families and government. The results from our modeling show that the societal costs outweighed the health costs (approximately 89.2% and 10.8%, respectively). The lifetime cost of familial intellectual disability is approximately AUD 7 million per person and AUD 10.8 million per household. The lifetime costs to families are second to those of the Australian Commonwealth government (AUD 4.2 million and AUD 9.3 million per household, respectively). These findings suggest that familial intellectual disability is a very expensive condition, representing a significant cost to families and government. Understanding the drivers of familial intellectual disability, especially societal, can assist us in the development of policies aimed at improving health outcomes and greater access to social care for affected individuals and their families.
Cervical cancer is one of the most severe threats to women worldwide and holds fourth rank in lethality. It is estimated that 604, 127 cervical cancer cases have been reported in 2020 globally. With advancements in high throughput technologies and bioinformatics, several cervical candidate genes have been proposed for better therapeutic strategies. In this paper, we intend to prioritize the candidate genes that are involved in cervical cancer progression through a fractal time series-based cross-correlations approach. we apply the chaos game representation theory combining a two-dimensional multifractal detrended cross-correlations approach among the known and candidate genes involved in cervical cancer progression to prioritize the candidate genes. We obtained 16 candidate genes that showed cross-correlation with known cancer genes. Functional enrichment analysis of the candidate genes shows that they involve GO terms: biological processes, cell-cell junction assembly, cell-cell junction organization, regulation of cell shape, cortical actin cytoskeleton organization, and actomyosin structure organization. KEGG pathway analysis revealed genes' role in Rap1 signaling pathway, ErbB signaling pathway, MAPK signaling pathway, PI3K-Akt signaling pathway, mTOR signaling pathway, Acute myeloid leukemia, chronic myeloid leukemia, Breast cancer, Thyroid cancer, Bladder cancer, and Gastric cancer. Further, we performed survival analysis and prioritized six genes CDH2, PAIP1, BRAF, EPB41L3, OSMR, and RUNX1 as potential candidate genes for cervical cancer that has a crucial role in tumor progression. We found that our study through this integrative approach an efficient tool and paved a new way to prioritize the candidate genes and these genes could be evaluated experimentally for potential validation. We suggest this may be useful in analyzing the nucleotide sequences and protein sequences for clustering, classification, class affiliation, etc.
The recommended dose of Tranexamic Acid Injection is 10 mg/kg actual body weight intravenously administered as a single dose, immediately before tooth extractions. Infuse no more than 1 mL/minute to avoid hypotension [see Warnings and Precautions (5.1)]. Following tooth extraction, Tranexamic Acid Injection may be administered for 2 to 8 days at a dose of 10 mg/kg actual body weight 3 to 4 times daily, intravenously.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

For intravenous infusion, Tranexamic Acid Injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions, and Dextran solutions. Heparin may be added to Tranexamic Acid Injection. Tranexamic Acid Injection should NOT be mixed with blood. The drug is a synthetic amino acid and should NOT be mixed with solutions containing penicillin.

Discard any unused portion.

The diluted mixture may be stored for up to 4 hours at room temperature prior to patient administration.
The Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) is a single use, disposable column packed with ultra-high molecular weight polyethylene (UHMWPE) beads. These beads have been modified to contain endpoint-attached heparin on the surface, thus forming a new chemical entity, the polymer now containing material of animal origin (porcine mucosa). The devices are sterilized using a standard ethylene oxide (EtO) cycle, following ISO 11135:2014.
Familial dysautonomia (FD) is a rare fatal autosomal recessive disease caused by a deficiency of the protein IKAP.1 This results in a selective developmental defect that affects mostly afferent (sensory) neurons including those in the dorsal root ganglia and cranial nerves.2, 3 We have shown recently that the protein deficiency impairs the development of afferent baroreceptor pathways, leaving the sympathetic efferent neurons reduced in number but functionally active. This results in the complete failure to detect and buffer fluctuations in blood pressure leading to volatile hypertension. In addition to the afferent baroreflex pathways, the deficiency of IKAP during embroyogenesis also affects the function of the chemoreflex pathways. As a result, patients fail to increase ventilation adequately in response to hypoxia and hypercapnia.4 As well as the impairment of the neurological mechanisms that regulate breathing, patients with FD also have a combination of obstructive, restrictive and probably also neuromuscular lung disease. Failure to coordinate swallowing results in recurrent bouts of aspiration pneumonia occurring from birth.5, 6 Imaging studies show that almost all patients with FD have bronchial wall thickening, atelectasis and almost 30% have bronchiectasis7. Pulmonary function tests show air flow limitation and associated lung restriction with reduction in diffusion capacity12. Sudden attacks of asthma like wheezing are common 8 and frequently associated with emotional upset,5 a time when sympathetic outflow to the vasculature is increased heightened.3 There is also a component of restrictive lung disease, with a very high incidence of scoliosis, which frequently begins at an early age. Complicating matters further, many patients opt to undergo spine fusion surgery, 9 which could potentially worsen further chest wall compliance.10 Patients with FD also lack muscle spindles, 2 making it likely that they have neuromuscular abnormalities arising from the absence of proprioceptive feedback from the respiratory muscles involved in the coordination of breathing.

Severe respiratory disease is a leading cause of death in patients with FD and many are treated empirically with inhaled bronchodilators. It is not known, however, whether these drugs are effective at reversing increased airway resistance. Hence, there is an urgent need to understand if the short acting beta-2-adrenergic agonist albuterol and the anticholinergic ipratropium, are effective bronchodilators. Furthermore, because treatment with these agents has potential cardiovascular side effects, we will also analyze their effects on blood pressure, heart rate and cardiac output.
A method of obtaining sterile, sedimented myxovirus (influenza, para-influenza, measles and mumps) from a liquid growth medium in which the virus has multiplied involves: (A) successively passing the growth medium through filter pads having the determined porosity of (i) relatively large pore filter (cellulosic pads, diatomaceous earth or spun glass), (ii) 0.8 to 2.0 micron pores (preferably 1.2 microns) and (iii) 0.22 to 0.6 micron pores (preferably 0.45 micron), and (B) centrifuging the filtrate in a 50,000 to 89,000 g field. The filtration may be preceded by a clarifying centrifugation of about 15,000 g. There should be about 100 sq. cm. of filter pad area for each 1 to 1.5 litres of the growth medium passed, and flow rates of I to 1.5 litres per 10 minutes. Air pressure of about 20 lbs. per sq. in. may be applied at each filtering step. The virus may be killed, e.g. with formalin, at any stage in the method. The final concentrated virus may be diluted with physiological phosphate buffer to produce a vaccine, or lyophilized for subsequent resuspension. Examples 1 and 2 are directed to the recovery of A2 and B strains of influenza, respectively, from their liquid growth medium.
1382073 A hypotensive and its isolation HOECHST AG 18 Feb 1972 [22 Feb 1971] 7625/72 Heading ASB  A hypotensive substance, having a melting point of 87C, soluble in water, pyridine, dimethyl formamide, dimethyl sulphoxide, ethanol, acids and methylene chloride, containing C 57.7%, H 7.06%, N 4.9%, O 24.4% and Cl 5.2% by weight, having the molecular formula C 38  H 56  O 12  N 3 Cl, a molecular weight from 780 to 800 calculated from the mass spectrum, a specific rotation [α]<SP>d</SP> 20  in water of -20, a UV spectrum showing no absorption in the range from 210 to 400 mÁ and a characteristic IR spectrum, is isolated by extracting dried Cabucala madagascariensis, particularly the branches, stems and roots thereof, with an aliphatic halogenated hydrocarbon, having up to 3 carbon atoms and up to 3 halogen atoms, e.g. trichloroethylene, trichloroethane, methylene chloride or chloroform, extracting the solution obtained with water, washing the aqueous solution with a carboxylic acid ester such as methyl formate, ethyl formate, methyl acetate or n-butyl formate, and drying the aqueous extract. The dried plant may be subjected to a preliminary extraction to remove fats, waxes and sterols with a C 5-7  hydrocarbon e.g. petroleum ether, pentane, or hexane. The active substance may be converted into a salt by adding equivalent amounts of the appropriate acid e.g. hydrochloric, phosphoric, acetic, lactic or tartaric acids. Pharmaceutical preparations comprise the active compound or a physiologically tolerable salt thereof in admixture or conjunction with a pharmaceutically acceptable carrier. The preparations may be administered orally or parenterally in the form of tablets, drageÚs or aqueous solutions.
Disclosed herein are methods for treating vascular disorders in mammals. The methods involve administering one or more agents selected from the group consisting of a heat shock protein, a therapeutically effective fragment and a therapeutically effective analog of a heat shock protein in a form suitable for mucosal administration. In some embodiments the heat shock protein of the method is mycobacterial HSP65. In some embodiments the heat shock protein is human HSP60. In some embodiments the heat shock protein is chlamydial HSP60. The method is of particular value in the treatment of atherosclerosis. Also disclosed are compositions useful for treating vascular disorders in mammals. The compositions include one or more agents selected from the group consisting of heat shock protein, therapeutically effective fragments and therapeutically effective analogs of said heat shock protein in aerosol or oral form. In some embodiments the heat shock protein of the composition is mycobacterial HSP65. In some embodiments the heat shock protein of the method is human HSP60. In some embodiments the heat shock protein is chlamydial HSP60. The composition is of particular value in the treatment of atherosclerosis.
Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
Acute respiratory tract infections (RTIs) are one of the most common causes of pediatric consultations/hospitalizations and a major trigger for asthma exacerbations. Some consensus statements have recommended the use of immunostimulants to boost natural defenses against severe or repeated infections. One of the most common immunostimulants is OM-85; while several randomized clinical trials (RCTs) have evaluated its efficacy in preventing acute RTIs and wheezing/asthma exacerbations, results have been conflicting. Similarly, various systematic reviews with meta-analyses (SRMs) on OM-85 have used different strategies, populations, and outcomes; moreover, SRM conclusions are limited when the original studies are highly heterogeneous or have a low quality, hindering the generalizability of the findings. Here we summarize the evidence on the effect of OM-85 to prevent acute RTIs, wheezing/asthma episodes, or loss of asthma control in children, by including and critically evaluating all SRMs published to date. We searched for SRMs on OM-85 in three publication databases and found nine SRMs (seven for RTI, and two for wheezing/asthma). Among those, one had a high confidence evaluation of quality (AMSTAR-2 tool) and found a reduction in the total number of acute RTIs among the OM-85 group. Overall, no strong recommendations can be derived from the existing literature, mainly due to the high heterogeneity among included RCTs and SRMs. Further, large, high-quality RCTs are needed to confirm the true efficacy of OM-85 for the prevention of acute RTIs, asthma development, and asthma exacerbations.
The present invention relates to a medical scan apparatus (10), comprising: an input unit (20); a processing unit (30); and an output unit (40). The input unit is configured to provide the processing unit with information regarding the power production capability of one or more power sources (60), and wherein a scan of a patient to be carried out by a medical imaging scanner (50) will utilize at least the one or more power sources. The processing unit is configured to predict the total energy that will be available to the medical imaging scanner over a time period, wherein the prediction comprises utilization of the information regarding the power production capability of the one or more power sources. The processing unit is configured to predict the instantaneous power that will be available to the medical imaging scanner during the time period, wherein the prediction comprises utilization of the information regarding the power production capability of the one or more power sources. The processing unit is configured to select a scan protocol for the medical imaging scanner to carry out the scan of the patient, wherein selection of the scan protocol comprises utilization of the predicted total energy that will be available to the medical imaging scanner over the time period and the predicted instantaneous power that will be available to the medical imaging scanner during the time period. The output unit is configured to provide the scan protocol to the medical imaging scanner.
Among those assigned to Group 1, participants who are Helicobacter pylori positive will receive Triple therapy and/or upper endoscopy. Participants with serological evidence of atrophic gastritis will undergo upper endoscopy and further endoscopic follow-up. H. pylori positive individuals will be offered Helicobacter pylori eradication as appropriate, independently of the pepsinogen results. From subjects in this group, breath samples will also be collected for volatile markers study. In addition, fecal occult blood test (FOBT) will be offered to this group as a benefit to participate in the study.
Biocompatible matrices or implants on which one or more specific cell-interactive molecules (“biomolecules”) can be immobilized have been developed. The matrices allow for the independent control of ligand concentration and matrix strength. In one embodiment, the matrix or implant is modified with one or more moieties capable of complexing bioconjugates prepared from one or more biomolecules. Suitable moieties include phenyl boronic acid complexing agents, such as salicylhydroxamic acid, which can complex to one or more biomolecules containing one or more phenyl boronic acid moieties. The biomolecules may be anchored to the matrix via a spacer molecule, which may allow for greater mobility of the biomolecules in aqueous solution. In one embodiment, the matrix is a hydrogel material which has been doubly-derivatized, wherein ligand concentration and matrix strength can be independently controlled. The matrices and implants can be used in vivo and in vitro applications including diagnostics, biosensors, bioprocess engineering, tissue engineering, regeneration and repair, and drug delivery.